Biocon Biologics' insulins facility in Malaysia receives EU GMP certification

25 Oct 2022 , 12:34 PM

Biocon Limited-led Biocon Biologics integrated insulins manufacturing facility in Malaysia is approved by the European Medicines Agency following a site inspection in July 2022.

The Company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland. This approval reflects the agency’s determination that the manufacturing facilities for Drug Substances, Drug Products, Insulin Delivery Device Assembly, as well as Secondary Packaging and Warehousing areas are in compliance with the guidelines of Good Manufacturing Practices.

This certificate enables the Company to continue addressing the needs of people with diabetes in the EU who require Insulin Glargine and Insulin Aspart.

“Biocon Biologics remains committed to the global standards of Quality and Compliance”, said Company’s Spokesperson.

At around 12:37 PM, Biocon Ltd is currently trading at Rs273 per share up by Rs2.8 or 1.04% from its previous closing of Rs270.20 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]